Cargando…

Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease

Sickle cell disease is a hemoglobinopathy that causes sickling of red blood cells, resulting in vessel blockage, stroke, anemia, inflammation, and extreme pain. The development and treatment of pain, in particular, neuropathic pain in sickle cell disease patients is poorly understood and impedes our...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Kimberlei, Sweatt, Nia, Tran, Huy, Apprey, Victor, Uthayathas, Subramaniam, Taylor, Robert, Gupta, Kalpna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025496/
https://www.ncbi.nlm.nih.gov/pubmed/32118032
http://dx.doi.org/10.3389/fmolb.2020.00005
_version_ 1783498522006388736
author Richardson, Kimberlei
Sweatt, Nia
Tran, Huy
Apprey, Victor
Uthayathas, Subramaniam
Taylor, Robert
Gupta, Kalpna
author_facet Richardson, Kimberlei
Sweatt, Nia
Tran, Huy
Apprey, Victor
Uthayathas, Subramaniam
Taylor, Robert
Gupta, Kalpna
author_sort Richardson, Kimberlei
collection PubMed
description Sickle cell disease is a hemoglobinopathy that causes sickling of red blood cells, resulting in vessel blockage, stroke, anemia, inflammation, and extreme pain. The development and treatment of pain, in particular, neuropathic pain in sickle cell disease patients is poorly understood and impedes our progress toward the development of novel therapies to treat pain associated with sickle cell disease. The orexin/hypocretin system offers a novel approach to treat chronic pain and hyperalgesia. These neuropeptides are synthesized in three regions: perifornical area (PFA), lateral hypothalamus (LH), and dorsomedial hypothalamus (DMH). Data suggest that orexin–A neuropeptide has an analgesic effect on inflammatory pain and may affect mechanisms underlying the maintenance of neuropathic pain. The purpose of this study was to determine whether there are neuronal activation differences in the orexin system as a result of neuropathic pain testing in a mouse model of sickle cell disease. Female transgenic sickle mice that express exclusively (99%) human sickle hemoglobin (HbSS-BERK) and age-/gender-matched controls (HbAA-BERK mice; n = 10/group, 20–30 g) expressing normal human hemoglobin A were habituated to each test protocol and environment before collecting baseline measurements and testing. Four measures were used to assess pain-related behaviors: thermal/heat hyperalgesia, cold hyperalgesia, mechanical hyperalgesia, and deep-tissue hyperalgesia. Hypothalamic brain sections from HbAA-BERK and HbSS-BERK mice were processed to visualize orexin and c-Fos immunoreactivity and quantified. The percentage of double labeled neurons in the PFA was significantly higher than the percentage of double labeled neurons in the LH orexin field of HbAA-BERK mice ((*)p < 0.05). The percentages of double labeled neurons in PFA and DMH orexin fields are significantly higher than those neurons in the LH of HbSS-BERK mice ((*)p < 0.05). These data suggest that DMH orexin neurons were preferentially recruited during neuropathic pain testing and a more diverse distribution of orexin neurons may be required to produce analgesia in response to pain in the HbSS-BERK mice. Identifying specific orexin neuronal populations that are integral in neuropathic pain processing will allow us to elucidate mechanisms that provide a more selective, targeted approach in treating of neuropathic pain in sickle cell disease.
format Online
Article
Text
id pubmed-7025496
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70254962020-02-28 Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease Richardson, Kimberlei Sweatt, Nia Tran, Huy Apprey, Victor Uthayathas, Subramaniam Taylor, Robert Gupta, Kalpna Front Mol Biosci Molecular Biosciences Sickle cell disease is a hemoglobinopathy that causes sickling of red blood cells, resulting in vessel blockage, stroke, anemia, inflammation, and extreme pain. The development and treatment of pain, in particular, neuropathic pain in sickle cell disease patients is poorly understood and impedes our progress toward the development of novel therapies to treat pain associated with sickle cell disease. The orexin/hypocretin system offers a novel approach to treat chronic pain and hyperalgesia. These neuropeptides are synthesized in three regions: perifornical area (PFA), lateral hypothalamus (LH), and dorsomedial hypothalamus (DMH). Data suggest that orexin–A neuropeptide has an analgesic effect on inflammatory pain and may affect mechanisms underlying the maintenance of neuropathic pain. The purpose of this study was to determine whether there are neuronal activation differences in the orexin system as a result of neuropathic pain testing in a mouse model of sickle cell disease. Female transgenic sickle mice that express exclusively (99%) human sickle hemoglobin (HbSS-BERK) and age-/gender-matched controls (HbAA-BERK mice; n = 10/group, 20–30 g) expressing normal human hemoglobin A were habituated to each test protocol and environment before collecting baseline measurements and testing. Four measures were used to assess pain-related behaviors: thermal/heat hyperalgesia, cold hyperalgesia, mechanical hyperalgesia, and deep-tissue hyperalgesia. Hypothalamic brain sections from HbAA-BERK and HbSS-BERK mice were processed to visualize orexin and c-Fos immunoreactivity and quantified. The percentage of double labeled neurons in the PFA was significantly higher than the percentage of double labeled neurons in the LH orexin field of HbAA-BERK mice ((*)p < 0.05). The percentages of double labeled neurons in PFA and DMH orexin fields are significantly higher than those neurons in the LH of HbSS-BERK mice ((*)p < 0.05). These data suggest that DMH orexin neurons were preferentially recruited during neuropathic pain testing and a more diverse distribution of orexin neurons may be required to produce analgesia in response to pain in the HbSS-BERK mice. Identifying specific orexin neuronal populations that are integral in neuropathic pain processing will allow us to elucidate mechanisms that provide a more selective, targeted approach in treating of neuropathic pain in sickle cell disease. Frontiers Media S.A. 2020-01-31 /pmc/articles/PMC7025496/ /pubmed/32118032 http://dx.doi.org/10.3389/fmolb.2020.00005 Text en Copyright © 2020 Richardson, Sweatt, Tran, Apprey, Uthayathas, Taylor and Gupta. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Richardson, Kimberlei
Sweatt, Nia
Tran, Huy
Apprey, Victor
Uthayathas, Subramaniam
Taylor, Robert
Gupta, Kalpna
Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease
title Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease
title_full Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease
title_fullStr Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease
title_full_unstemmed Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease
title_short Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease
title_sort significant quantitative differences in orexin neuronal activation after pain assessments in an animal model of sickle cell disease
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025496/
https://www.ncbi.nlm.nih.gov/pubmed/32118032
http://dx.doi.org/10.3389/fmolb.2020.00005
work_keys_str_mv AT richardsonkimberlei significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease
AT sweattnia significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease
AT tranhuy significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease
AT appreyvictor significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease
AT uthayathassubramaniam significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease
AT taylorrobert significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease
AT guptakalpna significantquantitativedifferencesinorexinneuronalactivationafterpainassessmentsinananimalmodelofsicklecelldisease